journal article·2025-03Open access

3D Printed Mesh Geometry Modulates Immune Response and Interface Biology in Mouse and Sheep Model: Implications for Pelvic Floor Surgery

Kallyanashis Paul, Saeedeh Darzi, Cathal D. O'Connell, David M. Z. B. Hennes, Anna Rosamilia, Caroline E. Gargett, Jerome A Werkmeister, Shayanti Mukherjee

Advanced Science· Volume 12· Issue 11

Abstract

Abstract Pelvic organ prolapse (POP) is a highly prevalent yet neglected health burden for women. Strengthening the pelvic floor with bioactive tissue‐engineered meshes is an emerging concept. This study investigates tissue regenerative design parameters, including degradability, porosity, and angulation, to develop alternative degradable melt electrowritten (MEW) constructs for surgical applications of POP. MEW constructs were fabricated in hierarchical geometries by two‐way stacking of the fibers with three different inter layer angles of 90°, 45°, or 22.5°. Implants printed at 22.5° have higher tensile strength under dry conditions and show better vaginal fibroblast (VF) attachment in vitro. In vivo assessment using preclinical mouse and ovine models demonstrates more effective degradation and improved tissue integration in 22.5° angular meshes compared to 90° and 45° meshes, with evidence of neo‐collagen deposition within implants at 6 weeks. The pattern and geometry of the layered MEW implants also influence the foreign body response, wherein the anti‐inflammatory phenotype shows a greater ratio of anti‐inflammatory CD206+ M2 macrophages/pro‐inflammatory CCR7+ M1 macrophages. This presents an attractive strategy for improving the design and fabrication of next‐generation vaginal implants for pelvic reconstructive surgery.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pelvic floor disorders treatments · Anorectal Disease Treatments and Outcomes · Hernia repair and management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Ritchie Centre Hudson Institute of Medical Research Clayton 3168 Australia

Department of Obstetrics and Gynaecology Monash University Clayton 3168 Australia

Biofab3D@ACMD St Vincent's Hospital Melbourne VIC 3065 Australia

Discipline of Electrical and Biomedical Engineering School of Engineering RMIT University Melbourne VIC 3000 Australia

Pelvic Floor Disorders Unit Monash Health Clayton VIC 3168 Australia

Funding

Monash University · Science and Industry Endowment Fund · National Health and Medical Research Council · Hudson Institute of Medical Research

References (84)

Show source-provided references
1. 10.3390/nano1006112010.3390/nano10061120 ↗
2. 10.1007/s00192-013-2169-910.1007/s00192-013-2169-9 ↗
3. 10.1016/S0029-7844(01)01472-710.1016/S0029-7844(01)01472-7 ↗
4. 10.1146/annurev-bioeng-061008-12482310.1146/annurev-bioeng-061008-124823 ↗
5. 10.1016/j.ajog.2005.02.02810.1016/j.ajog.2005.02.028 ↗
6. 10.1016/j.ajog.2018.07.02210.1016/j.ajog.2018.07.022 ↗
7. 10.1007/s13669-019-0256-810.1007/s13669-019-0256-8 ↗
8. 10.1002/uog.1489110.1002/uog.14891 ↗
9. 10.1111/1471-0528.1202010.1111/1471-0528.12020 ↗
10. 10.1007/s00192-015-2846-y10.1007/s00192-015-2846-y ↗
11. 10.1016/j.ajog.2021.03.01210.1016/j.ajog.2021.03.012 ↗
12. 10.1016/B978-0-12-800196-7.00013-X10.1016/B978-0-12-800196-7.00013-X ↗
13. 10.1111/1471-0528.1208510.1111/1471-0528.12085 ↗
14. 10.1016/j.ajog.2016.04.00810.1016/j.ajog.2016.04.008 ↗
15. 10.1016/j.actbio.2019.08.00310.1016/j.actbio.2019.08.003 ↗
16. 10.1007/s00192-017-3512-310.1007/s00192-017-3512-3 ↗
17. Syed K. K. · A Historical Perspective Urology · 2021 · 150 · 110
18. 10.1016/j.juro.2015.10.13810.1016/j.juro.2015.10.138 ↗
19. 10.1007/s00192-020-04525-910.1007/s00192-020-04525-9 ↗
20. 10.1002/ijgo.1293210.1002/ijgo.12932 ↗
21. Surgical Mesh for Transvaginal Repair of Pelvic Organ Prolapse in the Anterior Vaginal Compartment US Food and Drug Administration Maryland USA2019.
22. 10.1021/acs.biomac.8b0166110.1021/acs.biomac.8b01661 ↗
23. 10.1016/j.eururo.2009.01.05510.1016/j.eururo.2009.01.055 ↗
24. US Food and Drug Administration FDA takes action to protect women's health orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices www.fda.gov/news‐events/press‐announcements/fda‐takes‐action‐protect‐womens‐health‐orders‐manufacturerssurgical‐mesh‐intended‐transvaginal(accessed: July 2019).
25. 10.1098/rsfs.2018.008910.1098/rsfs.2018.0089 ↗
26. 10.1016/j.ajog.2016.09.07310.1016/j.ajog.2016.09.073 ↗
27. 10.1115/1.403905810.1115/1.4039058 ↗
28. 10.1002/jbm.a.3476710.1002/jbm.a.34767 ↗
29. 10.1016/j.jbiomech.2014.05.02710.1016/j.jbiomech.2014.05.027 ↗
30. 10.1016/j.ajog.2016.04.00810.1016/j.ajog.2016.04.008 ↗
31. 10.1097/SPV.000000000000008310.1097/SPV.0000000000000083 ↗
32. 10.1007/s00192-008-0737-110.1007/s00192-008-0737-1 ↗
33. 10.1016/j.actbio.2021.05.01510.1016/j.actbio.2021.05.015 ↗
34. 10.1016/j.ejogrb.2010.06.00810.1016/j.ejogrb.2010.06.008 ↗
35. 10.1038/s41467-020-20439-y10.1038/s41467-020-20439-y ↗
36. 10.1016/j.actbio.2022.08.05910.1016/j.actbio.2022.08.059 ↗
37. 10.1016/j.apmt.2020.10089010.1016/j.apmt.2020.100890 ↗
38. 10.1016/j.nano.2015.11.00610.1016/j.nano.2015.11.006 ↗
39. 10.1016/j.ajog.2019.04.02510.1016/j.ajog.2019.04.025 ↗
40. 10.3390/jpm1109084010.3390/jpm11090840 ↗
41. Shayanti M. · 2012
42. 10.1080/1465324090308036710.1080/14653240903080367 ↗
43. 10.1016/j.actbio.2019.08.00310.1016/j.actbio.2019.08.003 ↗
44. 10.1007/s00192-016-3206-210.1007/s00192-016-3206-2 ↗
45. 10.1016/j.mtbio.2020.10008110.1016/j.mtbio.2020.100081 ↗
46. 10.1016/j.biomaterials.2022.12180710.1016/j.biomaterials.2022.121807 ↗
47. 10.3390/ijms1009403310.3390/ijms10094033 ↗
48. 10.1016/j.biomaterials.2019.11949510.1016/j.biomaterials.2019.119495 ↗
49. 10.1097/AOG.0b013e3181f7372910.1097/AOG.0b013e3181f73729 ↗
50. 10.1007/s00192-017-3475-410.1007/s00192-017-3475-4 ↗
51. 10.1016/j.ejogrb.2019.01.01210.1016/j.ejogrb.2019.01.012 ↗
52. 10.1016/j.progpolymsci.2010.04.00210.1016/j.progpolymsci.2010.04.002 ↗
53. 10.1016/j.matdes.2024.11271710.1016/j.matdes.2024.112717 ↗
54. 10.1038/s41598-022-24275-610.1038/s41598-022-24275-6 ↗
55. 10.1016/j.mattod.2015.01.01910.1016/j.mattod.2015.01.019 ↗
56. 10.1097/SPV.000000000000100510.1097/SPV.0000000000001005 ↗
57. 10.3389/fphar.2020.0035310.3389/fphar.2020.00353 ↗
58. 10.1016/j.biomaterials.2019.11949510.1016/j.biomaterials.2019.119495 ↗
59. 10.1038/s41598-018-24919-610.1038/s41598-018-24919-6 ↗
60. 10.1089/ten.tec.2010.018210.1089/ten.tec.2010.0182 ↗
61. 10.1038/s41585-019-0230-210.1038/s41585-019-0230-2 ↗
62. 10.1111/1471-0528.1208510.1111/1471-0528.12085 ↗
63. 10.1016/j.jmbbm.2014.05.00510.1016/j.jmbbm.2014.05.005 ↗
64. 10.1111/1471-0528.1207710.1111/1471-0528.12077 ↗
65. 10.1007/s00192-008-0781-x10.1007/s00192-008-0781-x ↗
66. 10.1021/acs.macromol.3c0023410.1021/acs.macromol.3c00234 ↗
67. 10.1002/nau.2115610.1002/nau.21156 ↗
68. 10.1016/j.ajog.2015.08.07110.1016/j.ajog.2015.08.071 ↗
69. 10.1016/j.actbio.2022.05.05110.1016/j.actbio.2022.05.051 ↗
70. 10.1016/j.progpolymsci.2019.05.00410.1016/j.progpolymsci.2019.05.004 ↗
71. 10.3390/polym1416339710.3390/polym14163397 ↗
72. 10.1016/j.celrep.2015.10.06510.1016/j.celrep.2015.10.065 ↗
73. 10.1016/j.actbio.2019.07.03110.1016/j.actbio.2019.07.031 ↗
74. 10.1089/wound.2013.048510.1089/wound.2013.0485 ↗
75. 10.1016/j.smim.2007.11.00410.1016/j.smim.2007.11.004 ↗
76. 10.1002/adhm.20180145110.1002/adhm.201801451 ↗
77. 10.1038/s41598-020-58725-w10.1038/s41598-020-58725-w ↗
78. 10.1038/ncomms815810.1038/ncomms8158 ↗
79. 10.1016/j.cardfail.2014.11.00410.1016/j.cardfail.2014.11.004 ↗
80. 10.1016/j.actbio.2014.09.02210.1016/j.actbio.2014.09.022 ↗
81. 10.1002/adhm.20180145110.1002/adhm.201801451 ↗
82. 10.1111/1471-0528.1677810.1111/1471-0528.16778 ↗
83. 10.1038/srep4570910.1038/srep45709 ↗
84. 10.1117/1.JBO.21.12.12700810.1117/1.JBO.21.12.127008 ↗